HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations

Yong Du(Shanghai Research Institute of Building Sciences (China)), George Zhang(Shanghai Research Institute of Building Sciences (China))
Molecular Cancer Therapeutics
May 2, 2022
10.1158/1535-7163.mct-21-0835
Cited by 63

Related Papers

No related papers found

Powered by citation graph analysis